AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

Core Insights - AB Science's lead compound, masitinib, is highlighted as a potential breakthrough treatment for progressive multiple sclerosis (MS) due to its unique mechanism of action targeting mast cells and microglia [1][2][3] - Professor Patrick Vermersch, a prominent neurologist, emphasizes the significant role of neuroinflammation in neurodegenerative disorders, including MS, and the importance of addressing the pro-inflammatory activity of mast and microglial cells [1][2] - Phase IIB/III trials of masitinib have shown promising results in reducing neuroinflammation and slowing disease progression, with further phase III data expected to clarify which patient groups may benefit most [3] Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [5][6] - The company is headquartered in Paris, France, and is listed on Euronext Paris under the ticker AB [6] - Masitinib has been registered for veterinary medicine and is being developed for human medicine in various fields, including oncology and neurological diseases [6]